3-(4-fluorobenzyl)-N-((1r,4r)-4-hydroxycyclohexyl)-1H-pyrazole-5-carboxamide

ID: ALA5273864

Max Phase: Preclinical

Molecular Formula: C17H20FN3O2

Molecular Weight: 317.36

Names and Identifiers

Canonical SMILES:  O=C(N[C@H]1CC[C@H](O)CC1)c1cc(Cc2ccc(F)cc2)n[nH]1

Standard InChI:  InChI=1S/C17H20FN3O2/c18-12-3-1-11(2-4-12)9-14-10-16(21-20-14)17(23)19-13-5-7-15(22)8-6-13/h1-4,10,13,15,22H,5-9H2,(H,19,23)(H,20,21)/t13-,15-

Standard InChI Key:  PBSAFSLFKRRLNK-CTYIDZIISA-N

Molfile:  

 
     RDKit          2D

 23 25  0  0  0  0  0  0  0  0999 V2000
    4.7073   -0.3571    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    3.8823   -0.3571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4699   -1.0717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6449   -1.0717    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.2323   -0.3571    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6448    0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4698    0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4073   -0.3571    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.9949    0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4073    1.0717    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.1699    0.3572    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2426   -0.3573    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0497   -0.1857    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.1360    0.6348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3822    0.9704    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.8509    1.0476    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5659    0.6348    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.5659   -0.1906    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2762   -0.6026    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9929   -0.1943    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.9929    0.6344    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.2780    1.0469    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.7073   -0.6068    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  1
  3  2  1  0
  4  3  1  0
  5  4  1  0
  6  5  1  0
  2  7  1  0
  7  6  1  0
  5  8  1  6
  9  8  1  0
  9 10  2  0
 11  9  1  0
 11 12  1  0
 12 13  1  0
 13 14  2  0
 15 11  2  0
 15 14  1  0
 16 14  1  0
 17 16  1  0
 18 17  2  0
 19 18  1  0
 20 19  2  0
 21 20  1  0
 17 22  1  0
 22 21  2  0
 20 23  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5273864

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 317.36

Molecular Weight (Monoisotopic): 317.1540

AlogP: 2.17

#Rotatable Bonds: 4

Polar Surface Area: 78.01

Molecular Species: NEUTRAL

HBA: 3

HBD: 3

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 11.44

CX Basic pKa: 2.17

CX LogP: 1.79

CX LogD: 1.79

Aromatic Rings: 2

Heavy Atoms: 23

QED Weighted: 0.81

Np Likeness Score: -1.22

References

1. Jo M, Koizumi K, Suzuki M, Kanayama D, Watanabe Y, Gouda H, Mori H, Mizuguchi M, Obita T, Nabeshima Y, Toyooka N, Okada T..  (2023)  Design, synthesis, structure-activity relationship studies, and evaluation of novel GLS1 inhibitors.,  87  [PMID:37011768] [10.1016/j.bmcl.2023.129266]

Source

Source(1):

• Scientific Literature